This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ampio: The Freezer Killed My Osteoarthritis Drug

Ampio Pharmaceuticals (AMPE - Get Report) is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion. 

Apparently, shipments of Ampion and a placebo were exposed to freezing temperatures before the phase III study began, which might have messed with the drug's efficacy and safety. Ampio only just discovered this problem, so analysis of the study results -- expected this quarter -- will now be delayed, or the entire study may have be thrown out, the company claims.

Wowza. I've seen plenty of lame excuses for failed clinical trials in my day, but "the freezer killed my drug" is certainly creative. 

Nonsensical, too. Let's unpack the absurdities.

Here's Ampio CEO Michael Macaluso trying to explain what happened:

Pivotal clinical trial drug specifications dictate precise temperature and handling conditions for all study drug product in order to assure that the conclusions about the safety and effectiveness of the tested drugs will be accurate and repeatable during routine clinical use.  During the review of all documentation following the unblinding of the Study, our CRO determined that there were multiple instances where the in-package temperature monitor fell significantly below the 15 degrees C minimum required.

Ampio only discovered the Ampion temperature problem after the phase III study was unblinded. This means Ampio has the study results but is choosing not to disclose. The only "delay" appears to be in telling investors the Ampion osteoarthritis study failed. 

What is so special about Ampion that it must be kept above 15 degrees Celsius? That's the equivalent of 59 degrees Fahrenheit. If Ampion requires refrigeration, as some drugs most definitely do, the storage temperature would be around 40 degrees Fahrenheit. Requiring storage above 15 degrees Celsius, or 59 degrees Fahrenheit, doesn't sound like a product which requires refrigeration. Is Ampio telling us that Ampion is so fragile that it can't tolerate being stored in temperatures below 59 degrees Fahrenheit?

More from Macaluso:

Although our entire trial drug supply was housed, packaged, and shipped in early January by a specialized drug shipment vendor contractually obligated to maintain pre-determined temperature requirements under all conditions, our CRO discovered much of the drug product received at the clinical sites had been below the temperature requirement and may have been frozen for some period of time.  The drug temperature specifications were set because Ampion may lose potency if it is exposed to temperatures approaching freezing. We have contacted the FDA who has agreed to analyze the STEP trial as supportive data for our BLA.

Pre-determined temperature requirements? Like in the back of an unrefrigerated truck at room temperature?

Ampion is manufactured from human serum albumin, which can be stored between 2 degrees and 25 degrees Celsius. If albumin can be refrigerated down to an almost frozen state, then why can't Ampion also be refrigerated? Ampio claims its study blew up because Ampion's storage temperature fell below 15 degrees Celsius. But that makes no sense given the storage requirements for human serum albumin, the essential building-block component of Ampion.

Perhaps Ampio is using the temperature excuse to deflect from the fact the Ampion osteoarthritis study failed? 

Ampio has a lot more explaining to do. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs